National Bacterial Meningitis Study

Association Clinique Thérapeutique Infantile du val de Marne8,230 enrolled

Overview

Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data. The epidemiology of bacterialméningitis has changed in recent years, mainly owing to widespread use of different conjugate vaccines. The aim of this prospective national survey is to describe epidemiology of bacteria implicated in bacterial meningitis in children.

Study Type

OBSERVATIONAL

Enrollment

8,230

Conditions

Meningitis Children, Only Pneumococcal Conjugate Vaccine Meningococcal Vaccines H. Influenzae Vaccine Neonatal Infection Antibiotic Treatment Case Fatality Rate

Eligibility

Sex: ALLMin age: 0 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical signs of meningitis, associated with positive cerebrospinal fluid (CSF) culture and/or positive CSF antigen testing (Escherichia coli K1, N. meningitidis serogroups B, A, C, Y and W-135, group B streptococci, Hib, or S. pneumoniae), and/or positive CSF polymerase chain reaction (PCR), and/or positive blood culture with CSF pleocytosis (\> 10 cells/µL). * purpura fulminans Exclusion Criteria: \-

Outcomes

Primary Outcomes

mortality

Number of death according to age and bacteria

Time frame: before the hospital discharge

Secondary Outcomes

treatment failures

Number of antibiotic treatment failures according to bacteria after the control of lumbar puncture

Time frame: 48 hours after the antibiotic treatment and new lumbar puncture

impact of vaccines

Number of vaccination failures according to age, number of doses and bacteria

Time frame: before the hospital discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.